Acessibilidade / Reportar erro

Norfloxacin 0,3%* * CHIBROXIN (norfloxacino, MSD) - Cedido por Merck Sharp & Dohme. in the treatment of acute conjunctivitis and blepharoconjunctivitis

SUMMARY

Tolerability and efficacy of norfloxacin 0,3% ophthalmic solution were evaluated in 103 patients with acute conjunctivitis or blepharoconjunctivitis of presumed bacterial etiology. Symptoms improved clearly 24 to 48 hours after starting therapy. In 91,3% of patients no adverse reaction was detected. The most frequent causative agents were S. epidermidis and S. aureus, and the in vitro sensibility of these bacteria to norfloxacin was respectively 91,2% and 91,3%. These results confirm the potencial shown in in vitro studies for the use of norfloxacin in the treatment of superficial infections of the eye and adnexae.

Key words:
Conjunctivitis; blepharoconjunctivitis; quinolones; norfloxacin; susceptibilitytest

Conselho Brasileiro de Oftalmologia Rua Casa do Ator, 1117 - cj.21, 04546-004 São Paulo SP Brazil, Tel: 55 11 - 3266-4000, Fax: 55 11- 3171-0953 - São Paulo - SP - Brazil
E-mail: abo@cbo.com.br